Mason P C, Hosking B C, Nottingham R M, Cole D J W, Seewald W, McKay C H, Griffiths T M, Kaye-Smith B G, Chamberlain B
Mason Consulting, 317 Dunns Crossing Road, RD8, Christchurch 7678, New Zealand.
N Z Vet J. 2009 Feb;57(1):3-9. doi: 10.1080/00480169.2009.36861.
To evaluate the efficacy and safety of an oral formulation of the novel anthelmintic, monepantel (AAD 1566), in sheep, in comparison with some other anthelmintics currently registered in New Zealand.
A study was conducted on 18 farms located throughout the North and South Islands of New Zealand. On each farm, sheep naturally infected with the target nematodes were randomly assigned to groups, which were then treated with either monepantel, at a minimum dose rate of 2.5 mg/kg, or one of five other anthelmintics encompassing the range of single-entity and combination formulations that are commercially available in New Zealand, or left untreated as controls. Faecal samples were collected from all sheep pre-treatment (1-3 weeks before treatment), at the time of treatment, and approximately 1, 2 and 3 weeks after treatment (Days 7, 14 and 21). Faecal nematode egg counts (FEC) were measured in all samples, and the efficacy of treatments, as indicated by reductions in FEC, calculated. All sheep were inspected at least daily, to check for any adverse effects of treatment.
On all 18 farms, on Days 7, 14 and 21 (54 test points), the efficacy of the monepantel solution was >95%. At Days 7 and 14 post-treatment, efficacies>99% were recorded in 15 flocks. At Day 21 post-treatment, efficacies>98% were recorded in 13 flocks. Monepantel was as effective, or more effective, than the registered anthelmintics with which it was compared. Moreover, it was effective against strains of nematodes resistant to one or more of the currently available broad-spectrum anthelmintics. The monepantel solution used in this study was well tolerated by the sheep, and no adverse events could be attributed to its use.
When administered as an oral formulation under field conditions, at a minimum dose rate of 2.5 mg/kg, monepantel appeared to be highly effective against all the major genera of gastrointestinal nematodes of sheep, including Haemonchus, Teladorsagia (=Ostertagia), Trichostrongylus, Cooperia, Nematodirus, Chabertia and Oesophagostomum. This included strains resistant to the currently available broad-spectrum anthelmintics. Monepantel is the first compound from the recently discovered amino-acetonitrile derivative (AAD) class of anthelmintics to be developed for use in sheep.
与新西兰目前注册的其他一些驱虫药相比,评估新型驱虫药莫能菌素(AAD 1566)口服制剂对绵羊的疗效和安全性。
在新西兰北岛和南岛的18个农场进行了一项研究。在每个农场,将自然感染目标线虫的绵羊随机分组,然后分别用最低剂量率为2.5毫克/千克的莫能菌素、新西兰市售的五种其他单一成分或复方驱虫药之一进行治疗,或不治疗作为对照。在治疗前(治疗前1 - 3周)、治疗时以及治疗后约1、2和3周(第7、14和21天)从所有绵羊采集粪便样本。测量所有样本中的粪便线虫卵计数(FEC),并计算治疗效果,以FEC的降低表示。至少每天检查所有绵羊,以检查治疗的任何不良反应。
在所有18个农场,在第7、14和21天(54个测试点),莫能菌素溶液的疗效>95%。治疗后第7天和第14天,15个羊群的疗效>99%。治疗后第21天,13个羊群的疗效>98%。莫能菌素与所比较的已注册驱虫药一样有效或更有效。此外,它对耐一种或多种现有广谱驱虫药的线虫菌株也有效。本研究中使用的莫能菌素溶液绵羊耐受性良好,未发现可归因于其使用的不良事件。
在田间条件下以最低剂量率2.5毫克/千克口服给药时,莫能菌素似乎对绵羊胃肠道线虫的所有主要属,包括血矛线虫、细颈线虫(=奥斯特他线虫)、毛圆线虫、库珀线虫、细粒棘球绦虫、夏伯特线虫和食道口线虫,都非常有效。这包括对现有广谱驱虫药耐药的菌株。莫能菌素是最近发现的氨基乙腈衍生物(AAD)类驱虫药中首个开发用于绵羊的化合物。